Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 353-366

  Villabona, Lisa ^a   Andersson, Emilia ^a   Marchesi, Maddalena ^a   Masucci, Giuseppe V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ancestral haplotype 62.1; HLA genotyping; HLA A typing from formalin fixed paraffin embedded tissue DNA; Malignant melanoma; Survival

Indexed keywords

DNA; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR MARKER;

ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PATIENT; DNA EXTRACTION; GENE; GENE EXPRESSION; HAPLOTYPE; HLA TYPING; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ALLELES; DNA, NEOPLASM; FEMALE; GENOTYPING TECHNIQUES; HAPLOTYPES; HLA ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; NEOPLASMS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84891781904     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_18     Document Type: Article

References (37)

1. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315(6017): 301-305
2. Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL (1998) Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16(4):1430-1437
3. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI (2002) Presence of the human leukocyte antigen class II gene DRB1. *1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 9(6):587-593
4. Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferonalpha treatment. Int J Urol 3(6):435-440
5. Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J (2001) HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16(5):401-409
6. Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC (1997) Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75(2):283-286
7. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32(1):39-46
8. Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H (2002) Human leukocyte antigens and prognosis in patients with head and neck cancer: Results of a prospective follow-up study. Laryngoscope 112(4):651-657
9. Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the infl uenza nucleoprotein. Cell 42(2):457
10. Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of effi cient cancer vaccines? Scand J Immunol 70(6):516-525
11. Campoli M, Ferrone S (2008) Tumor escape mechanisms: Potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72(4):321-334
12. Algarra I, Collado A, Garrido F (1997) Protein bound polysaccharide PSK abrogates more effi ciently experimental metastases derived from H-2 negative than from H-2 positive fi brosarcoma tumor clones. J Exp Clin Cancer Res 16(4):373-380
13. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02. * genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61:1243-1253
14. Browning M, Dunnion D (1997) HLA and cancer: Implications for cancer immunotherapy and vaccination. Eur J Immunogenet 24(4): 293-312
15. Blomhoff A, Olsson M, Johansson S, Akselsen HE, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE, Lie BA (2006) Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1. *04 haplotypes. Genes Immun 7(2):130-140
16. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001) Linkage disequilibrium in the human genome. Nature 411(6834):199-204
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225-2229
18. Alper CA, Larsen CE, Dubey DP, Awdeh ZL, Fici DA, Yunis EJ (2006) The haplotype structure of the human major histocompatibility complex. Hum Immunol 67(1-2):73
19. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the Identification of common disease genes. Nat Genet 29(2):233-237
20. Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ, Dawkins RL (1992) Ancestral haplotypes: Conserved population MHC haplotypes. Hum Immunol 34(4):242
21. The MHC sequencing consortium (1999) Complete sequence and gene map of a human major histocompatibility complex. Nature 401(6756):921-923
22. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S (2004) Gene map of the extended human MHC. Nat Rev Genet 5(12):889-899
23. Thorsby E (1997) Invited anniversary review: HLA associated diseases. Hum Immunol 53(1): 1-11
24. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV (2006) Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103(1):145-150
25. De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, Van Der Zanden HG, Masucci G (2004) Correlation between HLAA2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality Rates. Med Oncol 21(1):49-52
26. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. (2012). Cancer Immunol Immunother 61(8):1243-1253
27. Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffi er B, Salles G, Warzocha K (2007) Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 46(5):500-507
28. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV (2009) The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58(10):1599-1608
29. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3(11):999-1005
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3(11):991-998
31. Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1-14
32. Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56(5): 709-717
33. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66(12):6405-6411
34. Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT (1996) Tumor escape from immune recognition: Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 2(4):641-652
35. Schipper RF, D'Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshoorn M (1997) HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 52(1): 54-71
36. Schipper RF, D'Amaro J, de Lange P, Schreuder GM, van Rood JJ, Oudshoorn M (1998) Validation of haplotype frequency estimation methods. Hum Immunol 59(8):518-523
37. Svejgaard A, Ryder LP (1994) HLA and disease associations: Detecting the strongest association. Tissue Antigens 43(1):18-27